|
|
Article: Immune Response Stock Drops After Test Results.(disappointing results for Remune, AIDS drug)(Brief Article)(Statistical Data Included)
- Article from:
- San Diego Business Journal
- Article date:
- June 11, 2001
- Author:
CopyrightCOPYRIGHT 2001 CBJ, L.P. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Biotech: Spanish Study Called Unimportant
CARLSBAD -- Stock in Immune Response Corp. lost more than half its value in one day after the company released disappointing trial results for Remune, its AIDS drug.
Yet shareholder reaction may have been out of proportion to the latest study's importance, one analyst said.
A 243-patient study conducted in Spain "probably doesn't mean very much," said Jim McCamant, editor at large with the Berkeley-based Medical Technology Stock Letter.
Immune Response reported June 1 that HIV-positive patients treated with Remune showed "no significant difference" from a group treated with a placebo.
...